22 March 2013
Common antibiotic linked to heart problems in patients with lung conditions
University of Dundee study adds to evidence of long term heart risks with some antibiotics
Research: Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies
The antibiotic clarithromycin - widely used for treating lower respiratory tract infections like pneumonia and acute exacerbations (sudden worsening) of chronic obstructive pulmonary disease (COPD)- may be associated with an increased risk of heart problems, finds a study published on bmj.com today.
The authors say their findings require confirmation, but add to a growing body of evidence suggesting a possible link between long term cardiovascular risks and certain antibiotics, known as macrolides.
Clarithromycin is often used to treat a sudden increase in symptoms for the progressive lung disease COPD - and in community acquired pneumonia - two of the most frequent causes of hospital admission in the UK. Previous studies have suggested that cardiovascular events, such as heart failure, heart rhythm problems, or sudden cardiac death, may be increased during treatment with clarithromycin, but the long term effects are still unclear.
So a team of UK researchers, led by the University of Dundee, set out to examine this association in more detail. They analysed data on 1,343 patients admitted to hospital with acute exacerbations of COPD and 1,631 patients admitted with community acquired pneumonia.
They classified all patients who received at least one dose of clarithromycin during their hospital visit as macrolide users and compared them with patients who did not receive any macrolide antibiotics during their visit. Over one year, 268 COPD patients and 171 pneumonia patients were admitted to hospital as a result of a cardiovascular event.
In all, after allowing for other factors, 73/281 (26%) of the patients prescribed clarithromycin during acute exacerbations of COPD had at least one cardiovascular event over the next year compared to 195/1062 (18%) of the patients who did not take this drug.
Among patients given clarithromycin for community acquired pneumonia, 123/980 (12.6%) had at least one cardiovascular event compared to 48/651 not on the drug (Hazard Ratio 1.69). There was no increased risk of acute coronary syndrome.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
For COPD, a significant association was also found between clarithromycin use and cardiovascular mortality, but not all cause mortality. In contrast, for community acquired pneumonia, no association was found between clarithromycin use and cardiovascular mortality or all cause mortality.
Longer durations of clarithromycin use were associated with more cardiovascular events. However, use of other types of antibiotics, such as ß-lactams, showed no association, suggesting an effect specific to clarithromycin, say the authors.
Overall, the results suggest that there will be an additional cardiovascular event for every eight patients given clarithromycin compared to patients not given the drug (or one in 11 for pneumonia).
The data also suggest that the increased risk may persist beyond the time when clarithromycin is stopped. This could be due to clarithromycin's effect on the body's inflammatory process in patients with chronic lung conditions.
The authors conclude that the findings "need to be validated in other datasets before recommendations to change practice can be made."
NOTES TO EDITORS
Public link to paper: www.bmj.com/cgi/doi/10.1136/bmj.f1235
For media enquiries contact:
Roddy Isles
Head. Press Office
University of Dundee
Nethergate, Dundee, DD1 4HN
TEL: 01382 384910
E-MAIL: r.isles@dundee.ac.uk
MOBILE: 07800 581902 |
